High Definition Colonoscopy (HDC) vs. Dye Spraying Chromo-colonoscopy (DSC) in Screening Patients With Long-standing Inflammatory Bowel Disease (IBD)
Primary Purpose
Inflammatory Bowel Diseases, Colon Dysplasia, Ulcerative Colitis
Status
Enrolling by invitation
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
High Definition Colonoscopy
Dye Spraying Chromocolonoscopy
Sponsored by
About this trial
This is an interventional screening trial for Inflammatory Bowel Diseases focused on measuring Colorectal cancer screening, Inflammatory bowel disease, Chromocolonoscopy, High definition white light colonoscopy
Eligibility Criteria
Inclusion Criteria:
- Patient age ≥18yr old
- History of UC or colonic Crohn's disease or unclassified colitis patients with or without colonic adenoma history
- Duration of ≥ eight years since diagnosis, or any duration with a diagnosis of primary sclerosing cholangitis
- Mucosal lesion involves ≥ 1/3 of the colon
Exclusion Criteria:
- History of colorectal cancer
- History of total colectomy
- Prior colonoscopy within the last 6 months
- Allergy to dye spray
- Poor bowel preparation
- Unable to provide informed consent
- Severe inflammation preventing visualization of the mucosa during the procedure.
Sites / Locations
- Beth Israel Deaconess Medical Center
- Lahey Hospital and Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
High Definition White Light Colonoscopy
Dye Spraying Chromo-colonoscopy
Arm Description
Outcomes
Primary Outcome Measures
Detection rate of dysplastic lesions in High Definition White Light Colonoscopy versus Dye Spraying Chromo-colonoscopy
Secondary Outcome Measures
Detection rate of Adenoma in both groups.
Detection rate of high-grade dysplasia in both groups.
Numbers of detected adenomas per patient.
Difference in withdrawal time to perform the procedure in both groups.
Difference in adverse event, mild (e.g.; nausea, vomiting, or abdominal pain that necessitate phone call from the patient to the provider, or sever (e.g.; GI bleeding, perforation, hospitalization after the procedure) for each arm.
Number of targeted chromoendoscopies
Appropriateness of reported follow up recommendations per standard guideline recommendations
Full Information
NCT ID
NCT04191655
First Posted
December 2, 2019
Last Updated
December 14, 2022
Sponsor
Beth Israel Deaconess Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT04191655
Brief Title
High Definition Colonoscopy (HDC) vs. Dye Spraying Chromo-colonoscopy (DSC) in Screening Patients With Long-standing Inflammatory Bowel Disease (IBD)
Official Title
High Definition Colonoscopy (HDC) vs. Dye Spraying Chromo-colonoscopy (DSC) in Screening Patients With Long-standing Inflammatory Bowel Disease (IBD)
Study Type
Interventional
2. Study Status
Record Verification Date
December 2022
Overall Recruitment Status
Enrolling by invitation
Study Start Date
April 3, 2019 (Actual)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
December 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Beth Israel Deaconess Medical Center
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Inflammatory Bowel Disease (IBD) involving the colon is a known risk for colon cancer. There are two standards-of-care colonoscopy techniques used for screening all patients who suffer from IBD for more than eight years. One method is to obtain random biopsies throughout the colon and the other is by using dye spraying chromo-colonoscopy.
This trial aims to study the difference between the two colonoscopy techniques during the era of high definition camera in detecting neoplastic lesions during screening patients with long-standing IBD.
Detailed Description
Research Question:
Is High Definition White Light Colonoscopy (HDWLC) not inferior to Dye Spraying Chromo-colonoscopy (DSC) in detecting all neoplastic lesions during screening patients with colonic IBD for more than eight years?
Study setting: The study will be conducted at Beth Israel Deaconess Medical Center. Patients will be randomized to HDWLC with biopsies every 10 cm versus DSC.
Study population: Adult patients colonic IBD for more than eight years.
Recruitment The study team will conduct a day by day chart review for all patients with a history of inflammatory bowel disease who were scheduled for screening colonoscopy and find candidates who meet the eligibility criteria. A study team member will meet with the potential candidates during their visit to the gastroenterology procedure room before having their colonoscopy and offer them to participate in the study.
Procedures: Participants will undergo either HDWLC with biopsies every 10 cm or DSC based on the randomization. Both procedures are standard of care and are being done at BIDMC before starting this study. All the endoscopists are IBD specialists with expertise in both procedures. All physicians were given a review article and video of chromoendoscopy to further standardize practice. The clinicians who are conducting the HDWLC are allowed to do a targeted DSC if required as per hospital protocol. Both arms of the study are using high definition Olympus colonoscopes
Study design: A randomized controlled, noninferiority trial.
Sample size:
Existing literatures suggest that the detection rate of the DSC arm is 20%. The investigators set 10% as the non-inferiority margin. With a total of 400 subjects (200 in each arm), the study will have 80% power to detect non-inferiority with the type I error rate controlled at 0.05. To account for a potential 25% data attribution, the study team will enroll 500 subjects.
Statistical Analysis:
The baseline characteristics of the two trial arms will first be tabulated for potential imbalance in variables. Continuous variables will be summarized by typical parameters such as mean, standard deviation and range and compared using two-sample T-test (if the normality assumption holds) or Wilcoxon rank-sum test (if the normality assumption does not hold). Normality of distribution will be determined using the Kolmogorov-Smirnov goodness-of-fit test. Categorical data will be summarized by frequency and percentage and analyzed using the Chi-square or Fishers exact test, as appropriate.
The primary outcome will be compared using Z-test based on normal approximation of the sample proportions.
Outcome analysis:
Primary outcome analysis: Intention to treat Secondary outcome analysis: Per protocol analysis.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Inflammatory Bowel Diseases, Colon Dysplasia, Ulcerative Colitis, Crohn Colitis, Indeterminate Colitis
Keywords
Colorectal cancer screening, Inflammatory bowel disease, Chromocolonoscopy, High definition white light colonoscopy
7. Study Design
Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
After patients consent to participate to the study, they will be randomized 1:1 by one of the study members who is blinded to the patient's history to either High Definition White Light Colonoscopy with biopsies every 10 cm or Dye Spraying Chromocolonoscopy. The gastroenterologist will be informed about the randomization result and s/he will conduct the procedure.
Masking
ParticipantCare ProviderInvestigator
Masking Description
In this study, we will randomize a total of 500 participants into two arms: A. high definition white light colonoscopy with biopsy (n=250) or B. chromocolonoscopy (n=250).
The randomization schedule was created by using GraphPad website. Then sealed opaque envelopes which numbered from 1 to 500 for all subjects were created based on the randomization schedules by one of the study co-investigators (Mohammed El-Dallal MD). These envelopes will be opened only by the endoscopy provider once the subject agrees and sings the informed consent. Of note, the randomization schedules will be saved in a separate document that only Mohammed El-Dallal MD has access to it. Neither the participants nor the study members (other than Mohammed El-Dallal MD) know about the assignment before opening the envelopes.
Allocation
Randomized
Enrollment
500 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
High Definition White Light Colonoscopy
Arm Type
Experimental
Arm Title
Dye Spraying Chromo-colonoscopy
Arm Type
Active Comparator
Intervention Type
Device
Intervention Name(s)
High Definition Colonoscopy
Intervention Description
A colonoscopy that used high definition (HD) camera
Intervention Type
Device
Intervention Name(s)
Dye Spraying Chromocolonoscopy
Intervention Description
A colonoscopy that used high definition camera in addition to dye spraying on the interior colon surface.
Primary Outcome Measure Information:
Title
Detection rate of dysplastic lesions in High Definition White Light Colonoscopy versus Dye Spraying Chromo-colonoscopy
Time Frame
Immediately after the procedure
Secondary Outcome Measure Information:
Title
Detection rate of Adenoma in both groups.
Time Frame
Immediately after the procedure
Title
Detection rate of high-grade dysplasia in both groups.
Time Frame
Immediately after the procedure
Title
Numbers of detected adenomas per patient.
Time Frame
Immediately after the procedure
Title
Difference in withdrawal time to perform the procedure in both groups.
Time Frame
Immediately after the procedure
Title
Difference in adverse event, mild (e.g.; nausea, vomiting, or abdominal pain that necessitate phone call from the patient to the provider, or sever (e.g.; GI bleeding, perforation, hospitalization after the procedure) for each arm.
Time Frame
Within one week from the procedure date
Title
Number of targeted chromoendoscopies
Time Frame
Immediately after the procedure
Title
Appropriateness of reported follow up recommendations per standard guideline recommendations
Time Frame
Immediately after the procedure
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient age ≥18yr old
History of UC or colonic Crohn's disease or unclassified colitis patients with or without colonic adenoma history
Duration of ≥ eight years since diagnosis, or any duration with a diagnosis of primary sclerosing cholangitis
Mucosal lesion involves ≥ 1/3 of the colon
Exclusion Criteria:
History of colorectal cancer
History of total colectomy
Prior colonoscopy within the last 6 months
Allergy to dye spray
Poor bowel preparation
Unable to provide informed consent
Severe inflammation preventing visualization of the mucosa during the procedure.
Facility Information:
Facility Name
Beth Israel Deaconess Medical Center
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Facility Name
Lahey Hospital and Medical Center
City
Burlington
State/Province
Massachusetts
ZIP/Postal Code
01803
Country
United States
12. IPD Sharing Statement
Learn more about this trial
High Definition Colonoscopy (HDC) vs. Dye Spraying Chromo-colonoscopy (DSC) in Screening Patients With Long-standing Inflammatory Bowel Disease (IBD)
We'll reach out to this number within 24 hrs